Literature DB >> 9467586

Presence of growth hormone secretagogue receptor messenger ribonucleic acid in human pituitary tumors and rat GH3 cells.

E F Adams1, B Huang, M Buchfelder, A Howard, R G Smith, S D Feighner, L H van der Ploeg, C Y Bowers, R Fahlbusch.   

Abstract

A novel G11-protein-coupled receptor specific for synthetic GH-releasing peptides (GHRPs) has recently been cloned and sequenced. Two forms exist, types 1a and 1b, the latter of which is biologically inactive. Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R). Both subtypes of GHS-R mRNA were detected in all six human pituitary somatotropinomas removed from patients with acromegaly. In culture, four of the tumors exhibited strong responses to GHRP-2 in terms of both phosphatidylinositol (PI) hydrolysis and GH secretion, but two were resistant. There was no apparent difference in the type 1a and type 1b expression pattern, as judged by RT-PCR, between responsive and nonresponsive tumors. Similarly, the rat pituitary tumor cell line, GH3, was found to express GHS-R mRNA, although these cells also did not respond to GHRPs. RT-PCR failed to detect GHS-R mRNA in eight functionless human pituitary tumors. In contrast, prolactinomas were found to express the receptor and, in culture, significant stimulation of PRL secretion and PI hydrolysis occurred in two of three tumors tested. These results demonstrate that tumorous somatotrophs express the GHS-R gene and that the occasionally observed nonresponsiveness of somatotropinomas to GHRPs is not due to the absence of the biologically active type 1a receptor. Additionally, human pituitary prolactinomas also express GHS-R and are able to respond to GHRPs in terms of PI hydrolysis and PRL secretion. In contrast, GHS-R gene expression does not appear to be associated with human functionless pituitary tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467586     DOI: 10.1210/jcem.83.2.4597

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Presence of ghrelin in normal and adenomatous human pituitary.

Authors:  M Korbonits; M Kojima; K Kangawa; A B Grossman
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 2.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Ghrelin reduces voltage-gated calcium currents in GH₃ cells via cyclic GMP pathways.

Authors:  Xuefeng Han; Yunlong Zhu; Yufeng Zhao; Chen Chen
Journal:  Endocrine       Date:  2011-08-27       Impact factor: 3.633

4.  Effects of the novel GH secretogogue, hexarelin on GH secretion and phosphatidylinositol hydrolysis by human pituitary somatotrophinomas in cell culture.

Authors:  Q Liu; T Lei; K Liu; X Bai; E Adams
Journal:  J Tongji Med Univ       Date:  1999

Review 5.  Ghrelin in neuroendocrine organs and tumours.

Authors:  Chrysanthia A Leontiou; Giulia Franchi; Márta Korbonits
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

6.  Effect of Bacterial Infection on Ghrelin Receptor Regulation in Periodontal Cells and Tissues.

Authors:  Andressa V B Nogueira; Marjan Nokhbehsaim; Anna Damanaki; Sigrun Eick; Svenja Beisel-Memmert; Christian Kirschneck; Agnes Schröder; Thamiris Cirelli; Natalia D P Leguizamón; Joni A Cirelli; James Deschner
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.